NHS fast-tracks new targeted drug for rare lung cancer
Patients eligible to receive Takeda’s Exkivity (mobocertinib) have a rare form of lung cancer that cannot be removed by surgery - News - PharmaTimes
Source: pharmatimes.com
Page 17 - Project Orbis News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Project Orbis. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Project Orbis Today - Breaking & Trending Today
Takeda's EXKIVITY▼(mobocertinib) granted Conditional Marketing Authorisation in Great Britain
Takeda UK Ltd. is pleased to announce that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted a conditional marketing authorisation to EXKIVITY (mobocertinib) in Great Britain as a monotherapy treatment for adult patients with epidermal growth factor receptor (EGFR) Exon 20 insertion ...
Source: pharmiweb.com
NHS Fast-Tracks Mobocertinib for Lung Cancer
NHS' deal with manufacturer Takeda, makes England the first in Europe to have the 'game changing' drug.
Source: medscape.com
NHS England Expediting Access to Takeda's Exkivity for Certain NSCLC Patients
The agency brokered a deal between NICE and Takeda, under which the sponsor will provide the drug on a budget-neutral basis while NICE completes its appraisal.
Source: precisiononcologynews.com
NHS approves 'game changing' lung cancer drug
A new drug targeting a rare kind of lung cancer could give patients two extra years of life after NHS drug watchdogs approving it for use. About 100 patients in England will benefit per year.
Source: dailymail.co.uk